Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 121INDUSTRY 4OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Specimen Handling 329Magnetic Resonance Spectroscopy 237Biopsy 199Nivolumab 57Cyclophosphamide 52X-Rays 48Carboplatin 46pembrolizumab 45Radiation 45Cisplatin 45Paclitaxel 44Immunoglobulin G 44Disulfides 44Taxes 43Platinum 411,2-diaminocyclohexaneplatinum II citrate 41Radiotherapy 36Doxorubicin 36Gemcitabine 32Ipilimumab 31atezolizumab 30CTLA-4 Antigen 30olaparib 28fludarabine 27venetoclax 25Vincristine 25Bevacizumab 25Prednisone 24cabozantinib 23Phantoms, Imaging 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Blood Specimen Collection × 90 days × Clear all
NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
57 enrolled
BreastOther solid neoplasm

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡